Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

BioCorRx (BICX) Short term Debt (2016 - 2024)

BioCorRx (BICX) has disclosed Short term Debt for 8 consecutive years, with $1.2 million as the latest value for Q3 2024.

  • Quarterly Short term Debt changed N/A to $1.2 million in Q3 2024 from the year-ago period, while the trailing twelve-month figure was $1.2 million through Sep 2024, changed N/A year-over-year, with the annual reading at $999088.0 for FY2023, N/A changed from the prior year.
  • Short term Debt hit $1.2 million in Q3 2024 for BioCorRx, up from $865353.0 in the prior quarter.
  • In the past five years, Short term Debt ranged from a high of $3.1 million in Q2 2022 to a low of $31580.0 in Q4 2021.
  • Historically, Short term Debt has averaged $1.8 million across 5 years, with a median of $2.3 million in 2020.
  • Biggest five-year swings in Short term Debt: increased 25.17% in 2020 and later plummeted 98.68% in 2021.
  • Year by year, Short term Debt stood at $2.4 million in 2020, then tumbled by 98.68% to $31580.0 in 2021, then surged by 9721.92% to $3.1 million in 2022, then tumbled by 67.79% to $999088.0 in 2023, then rose by 21.61% to $1.2 million in 2024.
  • Business Quant data shows Short term Debt for BICX at $1.2 million in Q3 2024, $865353.0 in Q2 2024, and $80190.0 in Q1 2024.